Vol.

No.

July 31, 2020Jul 31, 2020

Free

DOWNLOAD THE PDF

The COVID challenge: Maintaining progress in multiple myeloma clinical investigation

Cover Story

COVID-19 & Cancer Free Guest Editorial

The COVID challenge: Maintaining progress in multiple myeloma clinical investigation

By Hearn Jay Cho

The past two decades have brought hope to myeloma patients, as the majority benefit from the significant advances in chemotherapy.

Conversation with The Cancer Letter COVID-19 & Cancer Free

Stephen Nimer: Cancer patients are coming in for treatment, Florida's COVID-19 spike notwithstanding

By Paul Goldberg

Free

UC Davis cancer researcher with ties to PRC military charged with visa fraud

By Matthew Bin Han Ong

Conversation with The Cancer Letter Free

Raymond DuBois discusses his plans to navigate past the pandemic and take Hollings to comprehensive designation

By Paul Goldberg

Free Guest Editorial

The billion-dollar scrotal cosmesis solution: LHRH analogues, androgen suppression, and adherence

By Walter M. Stadler and Brian Heiss

COVID-19 & Cancer Free

Senate committee proposes $15.5 billion in COVID-19 relief for NIH

By Alexandria Carolan

COVID-19 & Cancer Free Letter To The Editor

AHIP: Health insurance providers are committed to improving access to telehealth

Clinical COVID-19 & Cancer Free Trials & Tribulations

Cancer care in the COVID-19 world: Adjusting to a new reality

By Marcus Neubauer

In Brief

Winship receives $7.8 million for multiple myeloma research

Jin, Wang receive $3.7 million from NCI to support research exploring link between cancer and HIV/AIDS

The Prostate Cancer Foundation and Robert F. Smith plan to address health disparities for African American men

Clinical Roundup

FDA, Syapse real-world study reveal higher risk of hospitalization and death among cancer patients with COVID-19, underscore health disparities

ACS updates guideline for cervical cancer screening

Clinical trial tests oral cancer drug to combat respiratory symptoms of COVID-19

Fox Chase researchers examine treatment toxicities in older esophageal cancer patients

Artificial intelligence identifies prostate cancer with near-perfect accuracy

Drugs & Targets

Tecentriq approved by FDA for BRAF V600 unresectable or metastatic melanoma

FDA approves first cell-based gene therapy for adult patients with relapsed or refractory MCL

Keytruda receives two sBLA acceptances from FDA in TNBC in indications

HIF-2α inhibitor MK-6482 receives FDA Breakthrough Designation for Von Hippel-Lindau Disease-associated RCC

Engineered macrophage immunotherapy receives IND clearance from FDA

BDTX-189 receives FDA Fast Track Designation for solid tumors harboring HER2 or EGFR mutations

Tagrisso receives FDA Breakthrough Therapy Designation for adjuvant treatment of stage IB-IIIA EGFR-mutated lung cancer

Piqray receives approval in Europe for HR+/HER2- advanced breast cancer with a PIK3CA mutation

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 05 - February 06, 2026